UCL spinout Autolus has filed for an initial public offering on Nasdaq and plans on using the proceeds to further develop its range of cancer treatments.
Autolus, a UK-based cancer-focused biopharmaceutical spinout from University College London (UCL), filed for a $100m initial public offering on Nasdaq on Monday.
Founded in 2014, Autolus is developing a range of immuno-oncology treatments that target both haematological and solid tumours. The spinout picked up an additional licence for an asset aimed at leukaemia and lymphoma last week.
The spinout is commercialising work by Martin Pule, a clinical senior lecturer in the Department of Haematology at UCL’s Cancer Institute. Pule…
